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A variety of psychiatric manifestations is known in
other organic diseases, such as systemic lupus erythematosus, Bechet's disease, lues, and Wilson's disease.
Diagnostic errors were made in those diseases also. British Journa!of Psychiatry, (1989), 155,413â€"415 Adverse Interaction Between Cimetidine and Chiorpromazine in Two Cases of Chronic Schizophrenia ALAN BYRNE and BRIAN O'SHEA
The treatment of two chlorpromazine-medicated chronic schizophrenics with cimetidine resulted in excessive sedation, which necessitated a reduction in chlorpromazine dosage. Eventual discontinuation of cimetidine therapy led to a return of schizophrenic symptoms, which responded to an increase in chlorpromazine dosage to previous levels.
Howes et a! (1983) reported that the chronic administration of cimetidine produces a fall in the steady-state plasma concentrations of chlorpromazine.
We present the case histories of two chronic schizophrenics seen in our hospital during July and August of 1987, which do not support this finding.
Case 1 which are eliminated by this oxidative pathway. The delayed clearances of diazepam (Klotz & Ruman, 1980) and oral anticoagulants (Flind, 1978) have been noted when cimetidine is administered concurrently, and it is our belief that chlorpromazine suffers a similar fate.
Chlorpromazine was originally introduced to potentiate the effects of cerebral depressants. It has also been noted to potentiate the actions of tricydic antidepressants, and this too is felt to involve reduced hepatic metabolism (Baldessarii, 1980) . It is interesting therefore, that cimetidine appears to potentiate the effects of chlorpromazine by its actions on hepatic microsomal enzymes. These effects on hepatic function have been noted before (e.g. Feely & Wormsley, 1983) , and we feel that the pronounced sedative effects in our patients are due to the impaired clearance of chlorpromazine.
An alternative explanation for this adverse reaction would be that cimetidine produces sedative effects of its own, which are added to those of chlor promazine. However, no antipsychotic activity has been attributed to cimetidine, despite its ability to cross the blood-brain barrier and produce both confusional and hallucinatory phenomena (Barnhart & Bowden, 1979 Bowden, 1979) . Cimetidine itself has been implicated in the impairing of renal function (McElligott, 1978) , but there was no evidence of renal impairment in either of our patients. Cimetidine has also been cited as a cause of stupor (Jefferson, 1979) and of reversible anxiety state (Johnson, 1979 ), but such reports are anecdotal.
Our two cases show how an interaction between two commonly used drugs produces excessive sedation which remits upon reduction of chlor promazine dosage. The binding of cimetidine to cytochrome P450 is felt to cause the problem, and as this mechanism is involved in the metabolism of haloperidol and other neuroleptics, a similar situation could arise in their use.
We suggest, therefore, that ranitidine might be a more appropriate anti-ulcer therapy for chronic schizophrenics, as it is not associated with alterations in the hepatic metabolism of other drugs. Our cases serve to warn clinicians of the possible complications of ulcer therapy for chronic schizophrenics stabilised on chlorpromazine.
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Case reports
Ms VT, a 53-year-old lady with mild mental handicap, a resident of a long-stay ward, was maintained on chlor promazine (100mg q.i.d. After about fivedays he becamedrowsyand lethargic, and took to bed. Following a reduction of his chlorpromazine dosage to 50 mg t.i.d. he became alert and active, and returned to his normal routine. Discontinuation of his cimetidine therapy was followed by a deterioration in his mental state. The latter improved markedly when his chlorpromazine dosage was doubled.
Discussion
We describe, for the first time, two cases of an adverse interaction between cimetidine and chlor promazine. Our suggestion is that this interaction causes a reduction in the metabolism of chlor promazine, with resultant sedation and deterioration in performance levels (McMillan et a!, 1978) .
The main pathways involved in the breakdown of chiorpromazine are oxidation and conjugation mechanisms (Baldessarii, 1980) , and it is in the oxidative mechanism that cimetidine is most likely to exert its effect. The findings of Feely & Wormsley (1983) suggest that cimetidine binds to the cyto chrome P450 oxidising system in hepatic microsomes, and so reduces the metabolism of the many drugs BAiDEssi@IuNI,R. J. (1980) Drugs and the treatment of psychiatric disorders.
In The Pharmacological Basis of Therapeutics Mianserin, a tetracycic piperazino-azepine compound, is a second-generation antidepressant that has attracted much attention since its introduction to clinical practice in 1975. In pre-ciical in-vitro studies, mianserin has been characterised as a moderate antagonist of pre-synaptic cv2-receptors, and as a poor blocker of serotonin uptake, without noticeable effect on acetylcholine receptors (Goodlet et a!, 1977) . Its overall efficacy is reported to be similar to that of conventional tricycic anti depressants (Zis & Goodwin, 1979) . Although mian serin lacks adverse cardiovascular effects and is distinguished by a lack of anticholinergic side-effects, it can cause several troublesome adverse effects:
drowsiness, blood dyscrasias, arthralgia, oedema, and hypotension. However, we have not found any reports of mianserin-induced restless legs syndrome in the literature.
The restless legs syndrome (similar to neuroleptic induced akathisia, which patients experience on lying down and attempting to fall asleep) is characterised by an unpleasant creeping sensation that affects primarily the legs, appears only at rest, and induces an irresistible urge to keep the limbs in motion (Montplaisir eta!, 1985) . We present what we believe to be the first three cases of mianserin-induced restless legs syndrome.
Case 1
Case reports
Mrs A, a 44-year-old married woman, met DSM-III criteria (American Psychiatric Association, 1980) for major depressive episode (dysphoric mood, slow speech, suicidal ideation, poor appetite, loss of energy, and insomnia).
Physical examination and routine laboratory tests were normal. Mental status examination on admission revealed both depressed mood and affect. The patient started a regimen of 30mg/day of mianserin, the dose increasing to 90 mg/day over one week. She became less suicidal and showed a definite improvement in mood and sleep.
